ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
CA045020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Protocol ID
CA045020 / NKTR-214
Condition/s
All paediatric cancer types
Diagnosis Stage
Relapsed/refractory
Sponsor
Bristol-Myers Squibb
Collaborators
Nektar Therapeutics
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 30 years
International registry ID's
NCT04730349
Back to Registry
Study Title CA045020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Protocol ID CA045020 / NKTR-214
Disease (Sub Disease) All paediatric cancer types
Diagnosis Stage Relapsed/refractory
Sponsor Bristol-Myers Squibb
Collaborators Nektar Therapeutics
Links https://clinicaltrials.gov/ct2/show/NCT04730349
Trial Status Closed to Recruitment
Trial Open Date 15/04/2021
Study Type Treatment
Phase Phase 1/2
Age Eligibility up to 30 years
International registry ID's NCT04730349

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.